Literature DB >> 17716547

Bleeding during critical illness: a prospective cohort study using a new measurement tool.

Donald M Arnold1, Laura Donahoe, France J Clarke, Andrea J Tkaczyk, Diane Heels-Ansdell, Nicole Zytaruk, Richard Cook, Kathryn E Webert, Ellen McDonald, Deborah J Cook.   

Abstract

PURPOSE: To estimate the incidence, severity, duration and consequences of bleeding during critical illness, and to test the performance characteristics of a new bleeding assessment tool.
METHODS: Clinical bleeding assessments were performed prospectively on 100 consecutive patients admitted to a medical-surgical intensive care unit (ICU) using a novel bleeding measurement tool called HEmorrhage MEasurement (HEME). Bleeding assessments were done daily in duplicate and independently by blinded, trained assessors. Inter-rater agreement and construct validity of the HEME tool were calculated using phi. Risk factors for major bleeding were identified using a multivariable Cox proportional hazards model.
RESULTS: Overall, 90% of patients experienced a total of 480 bleeds of which 94.8% were minor and 5.2% were major. Inter-rater reliability of the HEME tool was excellent (phi = 0.98, 95% CI: 0.96 to 0.99). A decrease in platelet count and a prolongation of partial thromboplastin time were independent risk factors for major bleeding but neither were renal failure nor prophylactic anticoagulation. Patients with major bleeding received more blood transfusions and had longer ICU stays compared to patients with minor or no bleeding.
CONCLUSIONS: Bleeding, although primarily minor, occurred in the majority of ICU patients. One of five patients experienced a major bleed which was associated with abnormal coagulation tests but not with prophylactic anticoagulants. These baseline bleeding rates can inform the design of future clinical trials in critical care that use bleeding as an outcome and HEME is a useful tool to measure bleeding in critically ill patients.

Entities:  

Mesh:

Year:  2007        PMID: 17716547     DOI: 10.25011/cim.v30i2.985

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  33 in total

1.  Safety and diagnostic yield of renal biopsy in the intensive care unit.

Authors:  Jean-François Augusto; Vincent Lassalle; Pierre Fillatre; Dominique Perrotin; Ferhat Meziani; Maleka Schenck-Dhif; Pierre Edouard Bollaert; Damien du Cheyron; Gaetan Beduneau; Christophe Vinsonneau; Christophe Guitton; Nicolas Lerolle
Journal:  Intensive Care Med       Date:  2012-07-10       Impact factor: 17.440

2.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Serious adverse events in academic critical care research.

Authors:  Deborah Cook; François Lauzier; Marcelo G Rocha; Mary Jane Sayles; Simon Finfer
Journal:  CMAJ       Date:  2008-04-22       Impact factor: 8.262

Review 4.  Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis.

Authors:  Sigrid Beitland; Irene Sandven; Lill-Kristin Kjærvik; Per Morten Sandset; Kjetil Sunde; Torsten Eken
Journal:  Intensive Care Med       Date:  2015-05-14       Impact factor: 17.440

5.  Bleeding Assessment Scale in Critically Ill Children (BASIC): Physician-Driven Diagnostic Criteria for Bleeding Severity.

Authors:  Marianne E Nellis; Marisa Tucci; Jacques Lacroix; Philip C Spinella; Kelly D Haque; Arabela Stock; Marie E Steiner; E Vincent S Faustino; Nicole D Zantek; Peter J Davis; Simon J Stanworth; Jill M Cholette; Robert I Parker; Pierre Demaret; Martin C J Kneyber; Robert T Russell; Paul A Stricker; Adam M Vogel; Ariane Willems; Cassandra D Josephson; Naomi L C Luban; Laura L Loftis; Stéphane Leteurtre; Christian F Stocker; Susan M Goobie; Oliver Karam
Journal:  Crit Care Med       Date:  2019-12       Impact factor: 7.598

6.  PROF-ETEV study: prophylaxis of venous thromboembolic disease in critical care units in Spain.

Authors:  Pablo García-Olivares; Jose Eugenio Guerrero; Pedro Galdos; Demetrio Carriedo; Francisco Murillo; Antonio Rivera
Journal:  Intensive Care Med       Date:  2014-08-20       Impact factor: 17.440

7.  Venous Thromboembolism Prophylaxis in Neurocritical Care Patients: Are Current Practices, Best Practices?

Authors:  K M Sauro; A Soo; A Kramer; P Couillard; J Kromm; D Zygun; D J Niven; S M Bagshaw; H T Stelfox
Journal:  Neurocrit Care       Date:  2019-04       Impact factor: 3.210

Review 8.  Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review.

Authors:  C Neunert; N Noroozi; G Norman; G R Buchanan; J Goy; I Nazi; J G Kelton; D M Arnold
Journal:  J Thromb Haemost       Date:  2015-01-14       Impact factor: 5.824

9.  2015 proceedings of the National Heart, Lung, and Blood Institute's State of the Science in Transfusion Medicine symposium.

Authors:  Steven L Spitalnik; Darrell Triulzi; Dana V Devine; Walter H Dzik; Anne F Eder; Terry Gernsheimer; Cassandra D Josephson; Daryl J Kor; Naomi L C Luban; Nareg H Roubinian; Traci Mondoro; Lisbeth A Welniak; Shimian Zou; Simone Glynn
Journal:  Transfusion       Date:  2015-08-10       Impact factor: 3.157

10.  Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis.

Authors:  François Lauzier; Donald M Arnold; Christian Rabbat; Diane Heels-Ansdell; Ryan Zarychanski; Peter Dodek; Betty Jean Ashley; Martin Albert; Kosar Khwaja; Marlies Ostermann; Yoanna Skrobik; Robert Fowler; Lauralyn McIntyre; Joseph L Nates; Tim Karachi; Renato D Lopes; Nicole Zytaruk; Simon Finfer; Mark Crowther; Deborah Cook
Journal:  Intensive Care Med       Date:  2013-08-14       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.